All posts by imreal

NfL in Real-World Clinical Settings, Upcoming Webinar Hosted by Xtalks


Clinicians are beginning to use NfL and are learning about how it can provide useful and important information for patient care.

Neurofilament light chain (NfL) protein has been well studied in a broad array of neurodegenerative diseases for years, and yet the specific parameters of its use in clinical settings have not yet been well established. Recently, Labcorp made NfL widely available as an orderable lab test for clinicians nationwide, but its prior unavailability has left questions about how it can be practically employed in patient workups and monitoring. Still, clinicians are beginning to use NfL and are learning about how it can provide useful and important information for patient care.

Register to understand what neurofilament light chain is and its importance in neurology, and ways that it may be practically used in patients with multiple sclerosis, concussion and amyotrophic lateral sclerosis (ALS).

Join Dr. Michelle Mielke, PhD, Professor, Epidemiology and Prevention, Wake Forest University School of Medicine; Dr. Nicholas Streicher, MD, MPH, MedStar Washington Hospital Center; Dr. Asya Wallach, MD, MS Center Physician, Holy Name Medical Center; and Dr. Joe Volpe (moderator), PhD, Scientific Discipline Director, Labcorp, for the live webinar on Thursday, October 27, 2022, at 1pm EDT (10am PDT).

For more information, or to register for this event, visit NfL in Real-World Clinical Settings.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Using Tech-Enabled Solutions to Amplify Diverse Clinical Trial Recruitment, Upcoming Webinar Hosted by Xtalks


With more than 2000 industry CEOs joining the CEO Action for Diversity & Inclusion Pledge, diversity in clinical trial recruitment has emerged as both a business and human priority.

The persistent lack of diversity in clinical trial recruitment has come to the fore as one of the most salient challenges to trial success. Now we are seeing research, policy and industry commitment combine to build unprecedented momentum for impactful change — as evidenced by the April 2022 draft guidance issued by the US Food and Drug Administration (FDA), shortly followed by the National Academies of Sciences, Engineering and Medicine’s publication of a consensus study report, Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups.

With more than 2000 industry CEOs joining the CEO Action for Diversity & Inclusion Pledge, diversity in clinical trial recruitment has emerged as both a business and human priority.

Being intentional about diversity is important not only because of the recent FDA guidance, but because greater diversity in clinical trials has the potential to yield long-term value, by enabling a more accurate understanding and demonstration of efficacy, safety and indication-specific patient populations — insights that can be used to optimize launch and marketing strategy.

This webinar will explore approaches for incorporating diversity-centric strategies into clinical development and how tech-enabled, human-centered solutions can enable companies to act on FDA guidelines, industry commitments and the ethical responsibility to communities for diverse and equitable clinical trials.

Register to learn more about amplifying diversity in clinical trial recruitment using tech-enabled solutions.

Join experts from Syneos Health, Monika Hirschbichler, VP, Program Strategy, Brooke Belk, VP, Omnichannel Strategy; Kasey Boynton, Sr. Director, Business Transformation; and Nick Kenny, Chief Scientific Officer, for the live webinar on Friday, October 28, 2022, at 11:30am EDT (4:30pm BST/UK).

For more information, or to register for this event, visit Using Tech-Enabled Solutions to Amplify Diverse Clinical Trial Recruitment.

ABOUT SYNEOS HEALTH

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs, and commercial capabilities to address modern market realities.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

How to Optimize Patient and Clinician Outcome Assessment Data (COA) in Early Phase Clinical Trials, Upcoming Webinar Hosted by Xtalks


Learn from industry authorities as they explore issues which impact data quality and patient burden for biotechs, pharma and CROs.

In this webinar, a team of expert panelists will answer key questions around the importance of Clinical Outcome Assessment (COA) data in early phase trials. They’ll take a deep dive into frequently asked questions around effective COA collection strategies including the debate between paper vs. electronic diaries, electronic COA (eCOA) collection in decentralized and hybrid trials, regulatory requirements and guidance on patient-reported data, benefits of real-time data access and more!

Learn from industry authorities as they explore issues which impact data quality and patient burden for biotechs, pharma and CROs.

Join Donna L. Reed, Consultant to the pharma industry; Bryan McDowell, MSc, MBA, Vice President, eCOA Clinical Science & Consulting; Kelly Dumais, PhD, Principal Scientific Advisor; and Chris Vogel (webinar moderator), Executive Director, eCOA Solutions, Clario, for the live webinar on Friday, October 28, 2022, at 9:30am EDT (3:30pm CEST/EU-Central).

For more information, or to register for this event, visit How to Optimize Patient and Clinician Outcome Assessment Data (COA) in Early Phase Clinical Trials.

ABOUT CLARIO

Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allow our partners to transform lives. Clario’s Trial Anywhere™ solutions have been powering hybrid and decentralized clinical trials (DCT) for over 20 years, enabling sponsors to collect high-quality endpoint data from any modality or location, all while improving patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory for over 5m patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

For more information, go to Clario.com or follow us on LinkedIn and Twitter.

Clario Media Contact

Duncan Cantor

Sr. Director, Corporate Communications

media@clario.com

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:



GLYTCH Energy® Launches Seven New Zero Sugar Formulas with Cognizin® Citicoline


When we were developing this new line, prioritizing gamer health and well-being was a top priority

GLYTCH, a revolutionary maker of wellness supplements, gamer energy and Revive hydration mixtures, that puts health and well-being first, has just launched a new energy line containing Cognizin® Citicoline. With seven flavors and more to come, these new products are targeted to the fast-growing esports market.

Cognizin® Citicoline, an innovative form of citicoline – is a brain health nutrient found naturally in the body,* and has been clinically studied to support brain health, focus, and attention. Kyowa Hakko Bio, health ingredient manufacturer of Cognizin® Citicoline, is “excited to have Cognizin® featured as a key component in GLYTCH energy,” says Maria Stanieich, Marketing Manager, Kyowa Hakko USA, Inc. “To have this new innovative formula in a market sector where gamers are always looking for an edge, we could not be happier.”

The seven GLYTCH Gaming Energy flavors are Moonbow, Predator, Falcon Smash, Vixen Lemonade, Aim Assis, Dragon Sweat and Azur Infusion. All the formulas are vegan and keto friendly, with no fillers, color additives, sugar or calories. The powders should be mixed with water or beverage of choice 20-30 minutes before game play, studying, workouts, or when you need to focus for work or play!

“When we were developing this new line, prioritizing gamer health and well-being was a top priority,” commented Benjamin Bullington owner of GLYTCH. “We are fanatical about the safety and efficacy of the ingredients we use, which is one of the reasons we do everything in house, including sourcing the best novel ingredients. Cognizin® Citicoline is backed by science, it really delivers as far as cognitive performance is concerned and it’s a safe and approved ingredient – everything we were looking for.”

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Cognizin® Citicoline

Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and branded form of Citicoline, a natural substance made endogenously in the body and especially vital to brain health.* Citicoline is a potent brain-health nutrient. A proprietary form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, attention, and memory. Cognizin® is manufactured through a fermentation process to yield high quality and high purity. Cognizin® is also highly stable, GRAS, pure and allergen-free. For more information on Cognizin®, visit https://cognizin.com/en

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com.

About Glytch

GLYTCH is revolutionizing the landscape of esports by prioritizing gamer health and well-being first. Creating top of the line supplements that amplify energy, focus, recovery and promote restful sleep – a lifestyle brand for all those looking to live the GLYTCH LYFE. A family owned and operated company GLYTCH, manages every part of the process in house, from sourcing, formulating, and manufacturing through to distribution. All GLYTCH formulas are unique and developed by a dedicated team of researchers and developers, to not only keep you playing hard, but to keep you healthy as well. For more details about GLYTCH products such as wellness supplements, gamer energy and Revive hydration mixtures, visit https://glytchenergy.com

Media interested in setting up an interview with Karen Todd, please contact Giselle Chollett: giselle@adinnyc.com or 917.386.7116.

Share article on social media or email:

NeuroFlow Closes $25M Growth Investment


NeuroFlow, the market leader in behavioral health integration technology, has secured $25 million in growth capital, led by SEMCAP Health.

With SEMCAP Health as a new strategic partner and investor, the company will continue to expand its groundbreaking referral network and deepen its relationships with payors and providers, determined to identify and triage individuals with behavioral health needs across the spectrum of care. Additionally, NeuroFlow will increase R&D investments to expand its technology platform, which alleviates pressure on providers caused by a growing number of behavioral health patients outstripping a finite supply of behavioral health resources — a longstanding issue made worse by the pandemic. The company will increase headcount across all departments to support rapid growth.

“NeuroFlow is different because we embrace collaboration with others in the space, like telehealth partners, to get people to the most efficient and effective care possible. Organizations, and people, need more than one approach. There is a significant supply and demand imbalance for behavioral health, and no efficient or scalable way to standardize the way people are identified, assessed, and referred. That’s why we exist,” explained NeuroFlow Chief Executive Officer Chris Molaro. “Since we were founded in 2017 the world has changed so much. Our growth has been fueled by both behavioral health finally being acknowledged and prioritized as well as payors and providers moving closer to value-based care. This financing round was opportunistic for us with a lead investor that is aligned with our vision and experienced in healthcare. We have the strength and flexibility to continue serving our health system and payor partners regardless of whatever the market conditions may be quarter-to-quarter.”

In the past year, the company has doubled in size (full-time employees) and has seen considerable adoption in the market by both major health systems and payors, expanding its reach of lives supported from 2 million to 15 million in all 50 states. Last month, the company moved into a state-of-the-art 16,000-square foot office in downtown Philadelphia to support a staffing increase and encourage more collaboration with key partners.

“NeuroFlow is the definitive leader in behavioral health integration because its technology effectively connects mental and physical health and supports integrated care models at scale,” said Ralph Muller, Executive Chairman, SEMCAP Health. “The company’s thoughtful approach to patient experience, enterprise workflows, and clinical content is helping healthcare organizations do more with less — clinicians use technology to engage millions of in-need patients to improve outcomes and reduce encounters in expensive, supply-constrained medical settings.”

“NeuroFlow fits perfectly into SEMCAP Health’s strategy of partnering with category leaders in their critical growth equity phase and amplifying their ability to improve healthcare quality, affordability, experience and health equity,” added Mark Miller, Managing Director, SEMCAP Health. “We are honored to help NeuroFlow advance its mission.” Miller joins the company’s Board of Directors in connection with the transaction.

About NeuroFlow

NeuroFlow assesses and triages people with behavioral health conditions to get them to the right level of care, providing high-tech and high-touch support for populations that would typically fall through the cracks in today’s healthcare system. Proven to drive better clinical and financial outcomes for hundreds of leading health systems, payors, and military organizations covering 15 million individuals, NeuroFlow’s platform combines consumer engagement with enterprise-level care management software to support behavioral health at scale. To learn more, visit http://www.neuroflow.com.

About SEMCAP

SEMCAP is a growth equity impact investor built to identify and invest in seminal trends that have the greatest impact on humanity – Healthcare, Education and Food & Nutrition. SEMCAP invests in companies across three verticals, which are underpinned by shifting government policy, technology, and consumer values, and are reframing the way business is conducted and how people live. Comprised of industry leading teams, globally recognized leaders, and advisory boards across these transformative investment verticals, SEMCAP seeks to create enduring value and generate above-market returns for investors. Through capital and strategic post-investment support, SEMCAP creates value for investors and empowers innovators to scale rapidly and deliver measurable positive outcomes for future generations. For more information please visit http://www.semcap.com.

About SEMCAP Health

SEMCAP Health is a distinctive investment platform within SEMCAP. Fueled by a leading investment team and a network of Senior Operating Advisors with deep operating and investing experience, SEMCAP Health makes growth equity investments in next generation healthcare technology and tech-enabled services businesses. SEMCAP Health invests with the intention to generate outsized financial returns while advancing healthcare quality, affordability, experience, and health equity. For more information about SEMCAP Health, please visit http://www.semcap.com/seminalhealthcare.

Share article on social media or email:

Latest ezW2 2022 Tax Preparation Software Just Released With SSA White Paper Printing Approval


News Image

ezW2 2022 Tax Preparation Software For White Paper Printing of W2 and W3 Copy A

With the latest ezW2 2022 software, customers can get a jump start on the upcoming tax season.

Brand new ezW2 2022 from Halfpricesoft.com just released for the upcoming tax season. Employers, HR managers and tax professionals of small to midsize businesses can now purchase the latest version of tax preparation software to get a jump start on the upcoming 2023 tax season. ezW2 makes it easy to file W2, W3, 1099-NEC and 1096 forms, in-house. Even better, the white paper printing feature for copy A W2 and W3 saves money on expensive forms.

“With the latest ezW2 2022 software, customers can get a jump start on the upcoming tax season.” said Halfpricesoft.com Founder, Dr. Ge.

Prices starting at only $49 for the small business paper printing version ($99 for the enterprise version) ezW2 software automates the process of completing, printing and filing all W2, W3, 1099-NEC and 1096 forms.

Please note: The IRS does not certify the substitute forms for 1099-NEC or 1096. If you mail the paper forms to the IRS, the red forms are required to fill out 1099-NEC Copy A and 1096.

Potential customers can download this software and test it for compatibility for up to 30 days with no obligation to purchase at https://www.halfpricesoft.com/w2_software.asp. The trial version will print forms with a TRIAL watermark and limit e-filing until the license key is purchased and added.

The main features included in the latest version include but are not limited to:


  • ezW2 software automates the process of completing, printing and filing all W2, W3, 1099-NEC and 1096 forms.
  • Prints all W2 forms (copy A, B, C, D, 1 and 2) and W3 on plain white paper. The black and white substitute forms of W2 Copy A and W3 are SSA-approved. No pre-printed forms are needed for SSA copies or recipient copies.
  • ezW2 can print 1099-NEC recipient copies on white paper. The IRS does not currently certify


white paper printing for Copy A so pre-printed forms are needed for only Copy A.

  • ezW2 can print W2 and 1099 recipient copies into digital PDF files and customers can email


forms easily

  • ezW2 saves customers valuable time by importing W2 and 1099 data from csv file – no need


for customers to enter the data one by one

  • ezW2 supports unlimited companies, recipients and forms at no extra charge, making it perfect for accountants, tax preparers and multi-business entrepreneurs as well as individual businesses

W2 1099 tax reporting is a breeze for new and seasoned customers. Download new ezW2 software today at: https://www.halfpricesoft.com/w2_software.asp . Compatible with Windows 10 systems. It can also run on Windows Vista, 7, 8 and 8.1 systems.

About halfpricesoft.com

Halfpricesoft.com is a leading provider of small business software,

including online and desktop payroll software, online employee attendance tracking software,

accounting software, in-house business and personal check printing software, W2, software,

1099 software, Accounting software, 1095 form software and ezACH direct deposit software.

Software from halfpricesoft.com is trusted by thousands of customers and will help small

Business owners simplify payroll processing and streamline business management.

Share article on social media or email:

Holganix Receives US Patent for Microbial Bionematicide Technology


Holganix Logo

Holganix Logo

“We are excited that the patent agency granted protection for our novel, microbial bionematicide technology and are looking forward to registering the product through the EPA, and commercializing it for agricultural and turf use,” states Holganix President of Agriculture, David Stark, Ph.D.

Holganix is an agricultural biotechnology company that develops microbial products used by farmers to increase yields, boost soil health, and reduce fertilizer requirements. Today Holganix announced it has been granted a US patent (US 11,447,427 B2) for a new microbial bionematicide technology. While studies are still ongoing, preliminary results have shown a 75% reduction in plant parasitic nematodes in a lab setting and an 80% reduction in a field setting.

The new bionematicide harnesses the power of soil microbes to reduce plant parasitic nematodes including soybean cyst, corn lesion, tomato root-knot, lance, and sting nematodes. The technology utilizes three modes of action: (1) it affects the migration of nematodes to the roots, (2) it inhibits eggs from hatching, and (3) it targets plant parasitic nematodes. The new bionematicide technology is still in development and is not yet commercialized or registered with the EPA.

“With these encouraging preliminary results and intellectual property, Holganix is positioned to develop a truly unique bionematicide product for the agriculture and turf industries,” explains Holganix President of Agriculture, David Stark, Ph.D. “Nematodes represent a $100 billion problem in terms of worldwide plant loss, and current solutions are often harmful to the soil and the environment. Because Holganix’s technology revolves around the use of a naturally occurring, concentrated, and stabilized stack of soil microbes, this bionematicide technology will be friendly for the environment.”

The patent (patent number: US 11,447,427 B2), entitled “Methods For Controlling Pathogenic Plant Nematodes and For Improving the Health and/or Performance of Ruminant Animals,” was awarded to inventors, David Stark, Ph.D., President of Agriculture at Holganix LLC and Robert Neidermyer, Ph.D., Director of Soil Health at Holganix LLC.

“We are excited that the patent agency granted protection for our novel, microbial bionematicide technology and are looking forward to continuing to develop the product, registering the product through the EPA, and commercializing it for agricultural, turf, and ornamental use,” explains Stark.

About Holganix:

Holganix is a manufacturer of microbial products that harness the power of soil microbes to build soil health, improve crop yield, and reduce the need for fertilizer. Holganix products allow farmers to improve their profit per acre, giving farmers the tools they need to drive both economic and environmental sustainability on the farm.

Share article on social media or email:

IHEARTPODCASTS INTRODUCES “POSITIVELY SEX! WITH LILA,” A NEW SERIES THAT CELEBRATES INTIMACY AND PLEASURE Hosted By Intimacy Specialist Lila Debuts October 13


PositivelySex with Lila-Logo

“As a society, we’ve become aware — more than ever before — of just how much we need intimacy in order to thrive,” said Lila. The world needs sex-positivity. Desperately! Now! That’s why I’m so incredibly delighted to have iHeartRadio in my corner.

iHeartRadio, the No. 1 podcast publisher globally according to Podtrac, today announced a new iHeartPodcast Original, “Positively Sex! with Lila”. Premiering October 13 and hosted by intimacy specialist Lila Donnolo, the weekly 46-episode series will explore intimacy of all kinds through a sex-positive talk show on timely, titillating, tender and taboo topics. Listeners can hear the official trailer now, HERE.

Founding member of New York’s premiere sex-positive intentional community, Hacienda Villa, and winner of Clubhouse’s Creator First Program, Lila will keep listeners coming back for more with a multitude of episode formats including editorialized segments, “on-the-street” style interviews, intimate one-on-one conversations, kiss-and-tell storytelling, talk show-esque roundtables, and more. “Positively Sex! with Lila” is designed for the curious and will cover sex, relationship, and intimacy topics listeners want to know about but don’t usually talk about. Lila will take audiences on a new journey every week by discussing fantasies and desires, pleasures and fetishes, relationships and casual sex, alongside practical, actionable techniques that listeners can apply immediately to enjoy a more pleasurable life.

“As a society, we’ve become aware — more than ever before — of just how much we need intimacy in order to thrive,” said Lila. “Most of us were indoctrinated with sexual shame, and this shame is detrimental to all aspects of our lives. The world needs sex-positivity. Desperately! Now! That’s why I’m so incredibly delighted to have iHeartRadio in my corner. iHeartRadio has given me, and sex-positivity, a global megaphone, and, to paraphrase my psychiatrist friend, I’m so excited for the world to get to hear these perspectives.”

“Positively Sex! with Lila” will celebrate intimacy and the right to design relationships the way listeners and their partner(s), see fit. In the first episode out now, Lila asks, “What is sex, anyway?” and will encourage listeners to overcome their preconceived notions and redefine sex. Throughout the series, she is laying it all out there with guests such as pro Dommes, therapists, doctors, kink masters, sex coaches, non-monogamous people, and folx on the street with opinions.

“Positively Sex! with Lila” is distributed by iHeartPodcasts and is available on the iHeartRadio app and anywhere podcasts are heard. New episodes post each Thursday.

“Positively Sex! with Lila” cover art is available for download HERE.

Follow @horizontalwithlila on Instagram for updates.

About Lila

Lila is an Intimacy Specialist, Public Speaker, Writer, & Performer. She’s had pillow talk with thousands of people (most of whom were not her lovers).

The daughter of a psychologist and a social worker, Lila is formerly the host of horizontal with lila, the podcast about intimacy of all kinds… entirely recorded while lying down. As a creator of immersive events, she hosts hot love talks, connection workshops, horizontal storytelling pajama parties, Femme Domme Kink Tasters, & a Valentine’s experience called 14 Rooms. Her BFA in Drama is from NYU’s Tisch School of the Arts / Experimental Theatre Wing.

Lila was a founding member of New York’s premiere sex-positive intentional community & event space, Hacienda Villa. She was a 2021 TED Idea Search Finalist and has brought her work on intimacy to SXSW, BoF VOICES, and conferences across the United States & in Bali, Indonesia. Lila’s independent podcast, horizontal with lila, was named “sexy, poetic, & eye-opening” and dubbed one of Marie Claire’s 35 Best Sex Podcasts of All Time. Visit http://www.horizontalwithlila.com for more information. PR/Media Contact: Nadine Jolson, jolsoncreativePR@mac.com

About iHeartMedia

iHeartMedia, Inc. [Nasdaq: IHRT] is the leading audio media company in America, reaching over 90% of Americans every month, and has a portfolio of unmatched consumer brands and industry-leading events. iHeart’s broadcast radio assets alone have more consumer reach in the U.S. than any other media outlet; twice the reach of the next largest broadcast radio company; and over four times the ad-enabled reach of the largest digital only audio service. iHeart is the largest podcast publisher according to Podtrac, with more downloads than the next four podcast publishers combined; has the number one social footprint among audio players, with seven times more followers than the next audio media brand; and is the only fully integrated audio ad tech solution across broadcast, streaming and podcasts. The company continues to leverage its strong audience connection and unparalleled consumer reach to build new platforms, products and services. Visit iHeartMedia.com for more company information. PR/Media Contact: Jenn Powers JennPowers@iHeartmedia.com

Share article on social media or email:



A journey of discovery” is an enjoyable and uplifting fiction that takes readers on an inspiring adventure


News Image

“Under the Potted Rose: A journey of discovery”: a heartfelt tale of lessons learned in unexpected places. “Under the Potted Rose: A journey of discovery” is the creation of published authors Nancy and John Chase, who have been married for over twenty-three years and have enjoyed serving in various missions, including spending ten years in the Republic of Panama as independent missionaries.

The Chases share, “Great! That’s just great! Just because I skipped out on that stupid economics class one too many times, I can’t graduate with the rest of my class. Now that horrible man, Principal Speace, is assigning me some lame ‘special assignment’ to earn my diploma. As if I haven’t already worked hard enough in the past twelve years. He gave me 50 days to get it done, and it looks like it will take every bit of that …

“Sara is 18 and ready to graduate high school, but because she has skipped class too many times, Principal Speace will not give her a diploma. She is faced with an ultimatum: either complete a special assignment that will last 50 days or return next semester to complete the class.

“Coming from an abusive, single-parent home, Sara is eager to graduate so she can get a job and move out on her own, so she grudgingly accepts the assignment.

“Each assignment is a mystery. When Sara completes an assignment and leaves her report under the potted rose in front of the school, she finds another brief note from Principal Speace about her next adventure.

“What follows are situations that challenge her in every way and shape the rest of her life.”

Published by Christian Faith Publishing, Nancy and John Chase’s new book is an enjoyable narrative that brings readers lessons on forgiveness, hard work, disappointment, and so much more.

The Chases share in hopes of bringing readers a thought-provoking and encouraging message of God’s grace within the pages of this charming Christian fiction.

Consumers can purchase “Under the Potted Rose: A journey of discovery” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Under the Potted Rose: A journey of discovery,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

David Jin, D.D.S. Has Been Reviewed and Approved by NJ Top Dentists For 2022


David Jin, DDS of A Beautiful Smile Dentistry

David Jin, DDS of A Beautiful Smile Dentistry

NJ Top Dentists has reviewed and approved David Jin, D.D.S. of A Beautiful Smile Dentistry for 2022. Dr. Jin delivers the highest quality cosmetic and restorative dentistry in the region — and has been treating everyone who walks through his door like family since 2003.

The doctors at A Beautiful Smile Dentistry understand that oral health is a vital part of your overall well-being and that preventive maintenance is the key to long term success in your overall health. To further improve the health and well being of our patients, A Beautiful Smile Dentistry has recently acquired Snore No More & Sleep Solutions, a multicenter sleep apnea medicine practice that has helped thousands of our first responders (police, firefighters and EMTs) to sleep better every night. This way, they can be in their best condition when our society needs them the most.

Dr. Jin, being an ex-US Navy officer, an ex-cop, and an ex-EMT, fully understands that first responders are the cornerstone of our society. He also understands the long and irregular shift hours that our first responders have to endure every day would most likely lead to sleep apnea and weight gain. As a means to pay back to our society, Dr. Jin has chosen to leverage Snore No More by ABS to provide sleep apnea treatment to our first responders.

A Beautiful Smile Dentistry is the industry leading expert in using technology to provide the best and most effective treatment in various dental specialty fields, such as dental implants, laser dentistry, InvisalignTM, and cosmetic dentistry. Now, by introducing modern technology to Snore No More & Sleep Solutions, their new Snore No More by ABS will be able to provide newer and better service to our first responders.

“We are committed to serving you with expert technology and gentle hands to create one beautiful smile at a time,” says Dr. Jin.

While Dr. Jin’s career began as an oral surgeon, his passion for cosmetic and restorative dentistry led him to general practice and sleep medicine. Today, with more than 25 years of experience, he offers his patients the latest in dental care and sleep medicine in a family-focused setting.

Dr. Jin has appeared on The Dr. Oz Show, Fox 5 News, iHeart Radio and the cover of Doctor of Dentistry magazine, in addition to having been recognized by The New Jersey Law Enforcement Journal, American Board of Dental Sleep Medicine and the American Dental Implant Association.

He has also been an instructor/professor at Harvard Dental School, Tufts University School of Dental Medicine, New York University College of Dentistry, Patterson Dental (CEREC) and he continues to teach at Hackensack University Medical Center.

To learn more about this NJ Top Dentist and his practice, please visit: https://njtopdocs.com/nj-dentists/drjin/

—-

About Us

NJ Top Dentists is a division of NJ Top Docs. NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email: